Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
JGR, that is not exactly true. The bonuses were paid in stock, not cash.
and magically find the millions needed for the advertisements, at the end of the rainbow?
Cytosorb surely knows that reimbursement in key to greater income. They do have a Reimbursement Manager.
Fabian Degener
Reimbursement Manager at CytoSorbents
Amsterdam Area, Netherlands
CytoSorbents
University of Groningen
As Reimbursement Manager at CytoSorbents I am responsible for obtaining coding/reimbursement for CytoSorb across its different licensed indications and across markets globally. Having worked as a management consultant for several years providing strategic advice and hands-on assistance to leading pharmaceutical and medical device companies, I have specialized myself within the areas of Market Access and HEOR. Originally trained as a molecular biologist with research experience at top institutes, including University of Groningen and Harvard Medical School; I stay committed to academic research through my part-time engagement as a PhD candidate in Pharmacoeconomics at the University of Groningen, The Netherlands.
Burnt, it is a fact that at least one person on this board, let's call him Paul has run multiple aliases here for years, the latest primary one as lakersrback. He has also run pumper aliases over the years and several of us have screen shots to prove it. Yes, that makes it a conspiracy to influence sentiment on the board. He runs the same game at times on the Yahoo board. Why would he/they make all of that effort except for gain. You can go to YouTube to view Jim Cramers video of him explaining how he manipulated markets in RH he past.
Is anyone else suspicious that as the sales price has dropped, 7 posters (maybe only 1) have continuously posted negative posts regarding the CEO? Same posters are posting negatively on the yahoo board. This has occurred before.
no burnt, where do you get the millions of dollars needed for the commercials that you want to air around the world?
Where are you going to get the millions for the TV ads for the US and the world burnt? But yes a Super Bowl ad of Cytosorb would be great.
JGR, I also am not happy with the share price. But, Dr. Chan did bring us the product to the EU, got it approved. He led the company from being a penny stock to the Nasdaq. Spread approval to 56 countries, HemoDefend on the way, two large heart studies in phase 3. He also apparently is very honest and hard working. There is no reason for the sales price being this low, pay attention to the posts about sales price manipulation.
Just another day of his manipulation of trying to push the share price down. In my opinion, that is the problem with share price, not the CEO. My guess is that it will continue until major news like HemoDefend, cancer, great quarter news, etc. occurs to jump start volume again.
That is exactly what I am saying. Anyone can claim to have X amount of shares. Your claims are always, yes always negative towards the company. I believe the average person would sell and move on if that disenchanted. What gets me suspicious is when the disenchanted gather like sharks, to cause negative sentiment as the share price falls. It is like they are reloading their swing trading holdings. I have seen this pattern numerous times here. Thus perhaps causing the same share price drops that you are accusing the CEO of.
ssmms,why do you exaggerate, what 6 star hotels? The Cowen conference in March was held at the Boston Marriott Copley, a 4 star hotel? You want them to stay at the mo tell motel? All of this exaggeration, misleading by you and pearsby, lakersrback is disconcerting. No coincidence that five aliases are attacking the company at the same time. I am also not happy with the sales price but believe it is due more to manipulation.
slappie, can you give one example of someone using the company as a personal cash cow? How about one PR that the PR company has not released?
it's not a vacation and it is okay with this shareholder if it helps the company.
So you are advocating adding another highly paid position, for sales? We have a director of sales already. Dr. Christian Steiner. I see 4 or maybe 5 posters here today, all in lock step, anti Dr. Chan. I don't think it is a coincidence that those same 4-5 post often at the same time, perhaps because they are the same person?
burnt, where are you seeing that? VetResQ was introduced over 2 years ago.
dah, I hope that you live to be a 100 and that CTSO soars above $100 with you. Thank you for your service as a moderator and contributor.
sloppie, do you even k ow what is salary is or his number of shares allocated? It could be zero in each case as far as I know.
key U.S. pilot study. Have I missed this before? From the BIO CEO & Investor Conference - Slideshow yesterday February 11, 2019, Slide 18 "Sepsis Trials: Numerous planned studies for 2019, including key U.S. pilot study." I don't recall mention of a U.S. sepsis trial beginning this year.
https://seekingalpha.com/article/4240305-cytosorbents-csto-presents-bio-ceo-and-investor-conference-slideshow?app=1
Let me get this right. Spectral Medical is seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock,by utilizing Toraymyxin to remove endotoxins, which can cause sepsis, from the bloodstream. CytoSorb-XL is a new, state-of-the-art porous polymer bead technology that combines lipopolysaccharide (LPS) endotoxin removal with the robust cytokine, toxin, and inflammatory mediator reduction achieved by CytoSorb. CytoSorb-XL is expected to eliminate the need for stand-alone endotoxin specific filters by offering superior performance in the removal of not just endotoxin, but a much broader array of inflammatory mediators that drive uncontrolled deadly inflammation, organ failure, and death in sepsis. This is from Cytosorb's website, so shouldn't Cytosorb XL put Spectral out of business when it comes online?
https://cytosorbents.com/cytosorbents-advances-war-on-sepsis-with-development-of-cytosorb-xl/
I don't feel a need for a disclaimer when everything in the article is factual. I did quote the source article.
CTSO: DSMB Recommends Continuance of REMOVE Study: Has several important implications. CytoSorbents (CTSO) announced this morning that the Data Safety Monitoring Board overseeing REMOVE, the company’s Germany-based study funded by the German government and which is evaluating safety and efficacy of CytoSorb in patients with infective endocarditis undergoing valve replacement surgery, recommended that the study continue.
The DSMB’s recommendation was based on an evaluation of the first 50 patients. The assessment, which included 28 patients in the CytoSorb cohort and 22 in the control group, analyzed cytokine and vasoactive mediator levels as “an indicator of the mechanistic mode of action” and found no device-associated adverse events in the CytoSorb group.
As a reminder, REMOVE is evaluating safety and efficacy of CytoSorb in patients with infective endocarditis undergoing valve replacement surgery. Primary endpoint is the difference in mean SOFA (Sequential Organ Failure Assessment) scores between experimental and control arms. Secondary endpoints include 30-day mortality, changes in cytokine levels, need for supportive care therapies such as vasopressors, mechanical ventilation, and dialysis, incidence of stroke, and the length of intensive care unit and in-hospital stay.
This study could be a win-win for CytoSorbents – potentially providing robust evidence of CytoSorb’s utility in a large and growing patient population (an already-completed 39-patient case study already indicated potential utility of CytoSorb in infective endocarditis, a growing problem among IV drug users which share dirty needles) – and doing so at little or no cost to the company as the study is being fully funded by the German government. Jena University Hospital is primary sponsor - Jena has been an important partner of CTSO’s over the years and manages the company’s International CytoSorb registry. B.R.A.H.M.S. (a division of Thermo Fisher Scientific) and the Fraunhofer Institute for Interfacial Engineering and Biotechnology are co-collaborators.
This DSMB 50-patient evaluation was a critical milestone as not only does it indicate there are no serious safety concerns, but its success was also a prerequisite for the German government to continue funding the study. And it holds potentially even greater importance when considering that success of REMOVE could eventually inform or even help dictate the company’s U.S. regulatory and commercialization decision-making.
Management recently noted that, given the robustness of the trial design, that it might be possible to use REMOVE as primary support (assuming positive results) for a future FDA filing for an infective endocarditis indication. As we noted in our recent update on CTSO, while it is way too early to guess the chances of that happening, positive results from this German study would certainly lend significant veracity to the likelihood of an eventual FDA approval for a similar indication whether it requires a U.S study or not.
As of CTSO’s Q3 earnings call on November 6th, 62 patients had enrolled in the study, which is expected to include a total of 250. While this morning’s press release does not disclose the number of patients that have been enrolled, it does note that enrollment “is inline with our goals, and we are confident in being able to advance this trial to completion.”
https://finance.yahoo.com/news/ctso-dsmb-recommends-continuance-remove-200000669.html
Actually lakersrback, there was an ebola bump for Cytosorb. See slides 23 and 24 from the Q22014 Cytosorb presentation. "CytoSorb may have benefit by reducing cytokine storm and sGP, buying time for the immune system to kill the virus". There was also a strategy for fighting ebola with Cytosorb on slide 24 "Our Strategy for outreach:
• WHO
• FDA
• CDC
• Government agencies such as USAMRIID (US Army Medical Research
Institute of Infectious Diseases)
• Non-profit organizations
• Hospitals treating Ebola patients inside/outside of West Africa
• Europe
• U.S.
https://cytosorbents.com/wp-content/uploads/2016/03/CytoSorbents_Q2_2014_Presentation.pdf
Public apology. My father in laws nephrologist post was an attempt at sarcasm. I along with you computed that since lakersrback is in his mid 70's, any father in law would be at least 100 years old.
clints, that is exactly what my uncle's nephrologist thinks! Nuff said!
colder, I doubt that Dr. June receives a salary, much less a "fat one". He is world class, a pioneer in CAR-T therapies has been named one of Time Magazine’s 100 most influential people in the world for 2018. " And while the U.S. strategy is currently focused on a cardiac surgery indication, it’s important to remember that CytoSorb could have effective utility in a number of different indications. One of which is sepsis and another is in cancer applications. While sepsis has been a significant topic of CTSO in the past, cancer has not received nearly as much attention (although CytoSorb has shown some utility in oncological applications). That could soon change, however. A few weeks ago CTSO announced that Dr, Carl June, an expert in CAR T-cell cancer immunotherapy, joined the company’s scientific advisory board for the purpose of guiding the strategy in oncology.
Just days prior to the Dr. June announcement, CTSO revealed that CytoSorb had been used successfully in several patients with a condition called hemophagocytic lymphohistiocytosis (HLH) – one of these was the subject of a case report published in early March in the Journal of Clinical Immunology. Studies have shown that subjects with secondary HLH, which is often caused by virologic infection and characterized by a strong and sometimes uncontrollable immune response – including cytokine release syndrome (CRS), can exhibit responses similar to cancer patients treated with certain immunotherapies. Specifically, severe CRS (i.e. severe inflammatory response with excessive and harmful levels of cytokines) which can lead to serious complications including organ failure and even death, has been associated with the use cancer immunotherapies such as CART-19 and blinatumomab as well as with secondary HLH. While corticosteroids and tocilizumab have been used with some success in controlling CRS, there are drawbacks. This includes that corticosteroids are suspected of potentially comprising immunotherapy efficacy. Relative to tocilizumab, researchers have noted that its use should be avoided if macrophage activating syndrome (MAS) is suspected.
The similarity in CRS response in HLH and cancer patients treated with immunotherapies and CytoSorb’s apparent early success in treating HLH patients (via reduction in inflammatory markers) is encouraging, particularly as it may relate to the leveraging the massive interest in and growth of the immunotherapy segment. CTSO notes in their March 20, 2017 press release that “we have confirmed the interest in the therapy, once available, as an adjunct to tocilizumab, and before high dose steroids are administered. We plan to continue to pursue applications of our therapy in the treatment of CRS in the United States, Europe, and elsewhere, as cancer immunotherapies continue to expand worldwide.”
So while cancer has been what we would characterize as a back-burner application – that could soon change given the recent hiring of Dr. June and the additional recent clinical work indicating CytoSorb’s potential utility in oncology-related areas."
https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2017/CTSO-Equity-Raise-Cancer-Applications-REFRESH-I-Data-Upcoming-article/default.aspx
B52T38, a friend of mine and I also compare CTSO to ISRG when we speak about the incredible potential of this company. The company itself is doing fine, adding new territories, new indications, new studies. partnerships. Management is really incredible with how they have managed to transform the company from a penny stock to where it is now. Sales are growing, management always stated that there could be some "lumpiness" between quarters. Shorts are having their way here, and there is a pattern, whenever the price sinks, there is always someone here (the alias may change, the person doesn't) that posts prolifically, and under several aliases. ISRG is $533 today, I do honestly believe that we will be there someday, make that some year, after US approval. After approval, there will be funds to fully exploit the other products, Universal Plasma, ContrastSorb and DrugSorb.
You try to effect sentiment of CTSO negatively. I will go further and state that eskay, lakersrback and ranchhand are all the same person.
You try to effect sentiment of CTSO negatively. I will go further and state that eskay, lakersrback and ranchhand are all the same person.
that is just not true lakersrback. The well known Greifswald study in Germany treated 22 patients with refractory sepsis, patients with approximately zero chance of survival. They were treated on their deathbeds with Cytosorb and 41% survived to the 28% mortality goal when 0 % was expected. The company is using the REFRESH2 trial to enter the US market earlier and then use it off label to treat sepsis.
well stated Jacque, we have a great product, great management team in place with a great plan.
My guess is with the share price down with good news, it is a short attack.This is reinforced in my mind by the negative comments that appear on this board at the same time.
Is Cytosorbents Corporation’s CEO Pay Fair? from Simply Wall Street of 1-18-19.
https://finance.yahoo.com/news/cytosorbents-corporation-nasdaq-ctso-ceo-192259933.html
I find it strange that everyone but lakersrback knows everything about HemoDefend.
lakersrback, the FDA sets the number of patients required for the trial, not you. It is finalnced by military and blood groups. Nuff said!
Dr. Chan has stated that this will be a small trial, perhaps with as few as 20 patients. It should go fast, and it was funded by the National Health Lung and Blood Institute, a division of NIH as well as US Special Operations Command.
that will be great getting the HemoDefend revenue, perhaps by the end of this year. I don't believe that analysts have considered it in their value of CTSO. Also, Dr. Chan stated "REFRESH 2-AKI has enrolled about 39 patients, with a target of completing the trial by 2020 and reaching FDA approval by 2021 to treat or reduce the severity of severe acute kidney injury." This is a much earlier, better and accurate timeline than others have pushed.
I see that Dr. Emil Paganini is a well respected nephrologist. I wonder if he knows lakersrback' father in laws nephrologist?
so we are back to $8.00 after hours, don't know how many shares.
I think he may have experimented on the higher level rats/mice, pearsby.
lakersrback, Dr. Chan spoke very well about the Greifswald sepsis study during his presentation today in San Francisco. The study with the worst cases of sepsis, refractory sepsis, which had not responded to any treatment and where the expected 28 day mortality was 0-10%. With treatment with Cytosorb, the 28 day mortality survival was an astonishing 41%! He stated that they were planning on a larger study to replicate the Greifswald findings. Apparently, Dr. Chan thinks more of the study than you do.
https://cytosorbents.com/data-presented-on-first-cytosorb-investigator-initiated-septic-shock-study/